M&A Deal Summary |
|
---|---|
Date | 2021-02-26 |
Target | Silicon Therapeutics |
Sector | Life Science |
Buyer(s) | Roivant Sciences |
Deal Type | Add-on Acquisition |
Deal Value | 450M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2014 |
Sector | Life Science |
Employees | 908 |
Revenue | 125M USD (2024) |
Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies. Roivant Sciences was founded in 2014 and is based in London, United Kingdom.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-10-23 |
Telavant
New York, New York, United States Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York. |
Sell | $7.1B |